CIK 0001505497 · Non-accelerated filer<br>Smaller reporting company
BioRestorative Therapies, Inc.
Sign in to watch- Ticker
- BRTX
- Exchange
- Nasdaq
- Industry
- Services-Misc Health & Allied Services, NEC
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 301341024
- Phone
- (631) 760-8100
- Business address
- 40 MARCUS DRIVE, SUITE ONE, MELVILLE, NY
- Former names
- Stem Cell Assurance, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 64 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-18 | ALSTODT LANCE President, CEO, COB | Purchase | +100 | $3.09 | $309 | 186,521 |
| 2023-01-09 | ALSTODT LANCE President, CEO, COB | Purchase | +100 | $3.08 | $308 | 186,121 |
| 2022-12-23 | ALSTODT LANCE President, CEO, COB | Purchase | +200 | $3.02 | $604 | 185,921 |
| 2022-12-23 | ALSTODT LANCE President, CEO, COB | Purchase | +100 | $2.99 | $299 | 186,021 |
| 2022-12-07 | ALSTODT LANCE President, CEO, COB | Purchase | +1,800 | $2.99 | $5K | 185,721 |
| 2022-11-30 | Broadrick Dale 10% owner | Purchase | +100 | $2.78 | $278 | 298,973 |
| 2022-11-30 | Broadrick Dale 10% owner | Purchase | +100 | $2.77 | $277 | 299,073 |
| 2022-11-21 | Silva Francisco VP of Research and Development | Purchase | +943 | $2.62 | $2K | 166,046 |
| 2022-11-18 | ALSTODT LANCE President, CEO, COB | Purchase | +1,000 | $2.88 | $3K | 183,921 |
| 2022-11-03 | Paccasassi Robert VP, QA and Reg Compliance | Returned to the company · Stock Option | −8,277 | 0 | ||
| 2022-11-03 | Paccasassi Robert VP, QA and Reg Compliance | Grant or award · Stock Option | +8,277 | 8,277 | ||
| 2022-11-03 | Silva Francisco VP of Research and Development | Returned to the company · Stock Option | −293,479 | 0 | ||
| 2022-11-03 | Silva Francisco VP of Research and Development | Grant or award · Stock Option | +293,479 | 293,479 | ||
| 2022-11-03 | Silva Francisco VP of Research and Development | Returned to the company · Stock Option | −42,059 | 0 | ||
| 2022-11-03 | Silva Francisco VP of Research and Development | Grant or award · Stock Option | +42,059 | 42,059 | ||
| 2022-11-03 | Kristal Robert Eugene Chief Financial Officer | Returned to the company · Stock Option | −10,490 | 0 | ||
| 2022-11-03 | Kristal Robert Eugene Chief Financial Officer | Grant or award · Stock Option | +10,490 | 10,490 | ||
| 2022-11-03 | Kukekov Nickolay V. Director | Returned to the company · Stock Option | −25,236 | 0 | ||
| 2022-11-03 | Kukekov Nickolay V. Director | Grant or award · Stock Option | +25,236 | 25,236 | ||
| 2022-11-03 | Williams Patrick F. Director | Returned to the company · Stock Option | −10,490 | 0 |
Page 4 of 30 · 598 trades